#USA #Los Angeles #securities lawsuit #DJS Law Group #Capricor Therapeutics

Capricor Therapeutics Faces Class Action Lawsuit

Capricor Therapeutics, Inc., a biotechnology company focused on developing innovative therapies, is now at the center of a class action lawsuit that has significant implications for its investors. This lawsuit, filed by the DJS Law Group, highlights serious allegations against the company regarding violations of the Securities Exchange Act.

Background of the Case

The allegations focus on Capricor's public statements relating to its drug Deramiocel, which is under review for and sought approval from the FDA. The crux of the problem lies in claims that the company made misleading assertions about the effectiveness and safety data of Deramiocel. Investigations revealed that Capricor altered the statistical analysis plan utilized during clinical trials without the prior consent of the FDA. Moreover, it resubmitted a Biologics License Application for Deramiocel based on these modified plans, which raises significant concerns about the integrity of its communications to investors.

Investors who purchased shares during the class period, which extends from December 17, 2025, until July 26, 2026, are encouraged to evaluate their involvement. The deadline for investors wishing to participate in this case is September 28, 2026.

What This Means for Investors

For shareholders who feel they have suffered losses due to the misleading statements made by Capricor, this lawsuit represents a potential avenue for financial recovery. The DJS Law Group has emphasized that one does not need to be appointed as a lead plaintiff to recover losses through this class action suit. Therefore, all affected shareholders should take the necessary steps to protect their interests and seek guidance from the DJS Law Group.

Legal Expertise of DJS Law Group

The DJS Law Group has established itself as a formidable advocate for investors, specializing in class action lawsuits and corporate governance issues. Founded by partners with extensive backgrounds in securities law, including David Schwartz, the firm is known for its aggressive approach in handling complex legal matters. Their track record in securing favorable outcomes for clients reflects their capacity to manage intricate legal claims against large corporations.

This case against Capricor is not just about the potential financial losses of individual investors; it's also about holding corporations accountable for their actions and ensuring that transparency in communications is maintained. By participating in this class action, shareholders are taking a stand against misleading corporate practices that undermine investor trust.

If you believe you have been adversely affected by Capricor's alleged actions, it may be prudent to reach out to the DJS Law Group for a consultation. They can provide further insights into your rights as an investor and what steps you may need to take next.

Summary

As the lawsuit unfolds, the implications for Capricor and its shareholders could be profound. Each investor's situation will vary, and it's essential to seek expert legal advice tailored to your unique circumstances. The upcoming deadlines and the details of the case will be crucial for those affected by the tumultuous events surrounding Capricor Therapeutics, Inc. This is a developing story and one to continue to watch carefully as more information becomes available.